Calendar

Mar
25
Thu
2021
MIPS Seminar - Shan X. Wang, PhD @ Zoom - See Description for Zoom Link
MIPS Seminar – Shan X. Wang, PhD
Mar 25 @ 12:00 pm – 12:45 pm Zoom - See Description for Zoom Link
MIPS Seminar - Shan X. Wang, PhD @ Zoom - See Description for Zoom Link

MIPS Seminar Series: “Circulating Tumor DNA Biomarkers for Therapy Monitoring and Early Detection”

Shan X. Wang, PhD
Leland T. Edwards Professor in the School of Engineering
Professor of Materials Science & Engineering, jointly of Electrical Engineering, and by courtesy of Radiology (Stanford School of Medicine)
Director, Stanford Center for Magnetic Nanotechnology
Stanford University

 

Location: Zoom
Webinar URL: https://stanford.zoom.us/s/93202777468
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 932 0277 7468
Passcode: 851144

12:00pm – 12:45pm Seminar & Discussion
RSVP Here

 

ABSTRACT
Inspired by Dr Sam Gambhir, MIPS, Canary Center, and Stanford CCNE have pursued in vivo imaging and in vitro diagnostic tests for cancer therapeutic response or early detection, respectively, over the last 15+ years. Here I present two successful examples based on circulating tumor DNA (ctDNA) targets in plasma, complementary to imaging modalities such as CT and Ultrasound.

We have developed a simple yet highly sensitive assay for the detection of actionable mutational targets such as Epidermal Growth Factor Receptor (EGFR) and Kirsten rat sarcoma oncogene (KRAS) mutations in the plasma ctDNA from non-small cell lung cancer (NSCLC) patients using giant magnetoresistive (GMR) nanosensors. Our assay achieves lower limits of detection compared to standard fluorescent PCR based assays, and comparable performance to digital PCR methods. In 30 patients with metastatic disease and known EGFR mutation status at diagnosis, our assay achieved 87.5% sensitivity for Exon19 deletion and 90% sensitivity for L858R mutation while retaining 100% specificity; additionally, our assay detected secondary T790M mutation resistance with 96.3% specificity while retaining 100% sensitivity. We re-sampled 13 patients undergoing tyrosine kinase inhibitor (TKI) therapy 2 weeks after initiation to assess response, our GMR assay was 100% accurate in correlation with longitudinal clinical outcome, and the responders identified by the GMR assay had significantly improved progression free survival (PFS) compared to the non-responders. The GMR assay is low cost, rapid, and portable, making it ideal for detecting actionable mutations at diagnosis and non-invasively monitoring treatment response in the clinic.

On another front, we have also developed a highly sensitive and multiplexed assay for the detection of methylated ctDNA targets in plasma samples. Current diagnostic tests for liver cancer in at-risk patients are cumbersome, costly and inaccurate, resulting in a need for accurate blood-based tests. By devising a Layered Analysis of Methylated Biomarkers (LAMB) from the relevant big data, we have discovered a set of DNA targets in the blood that accurately detects liver cancer in these at-risk patients. This set of methylated targets was found by analyzing the genetic information of 3411 liver cancer patients and 1722 healthy people. Our results could lead to clinical adoption of liquid biopsy tests for liver cancer surveillance in high-risk populations and the development of blood tests for other cancers.

 

ABOUT
Prof. Wang directs the Center for Magnetic Nanotechnology and is a leading expert in biosensors, information storage and spintronics. His research and inventions span across a variety of areas including magnetic biochips, in vitro diagnostics, cancer biomarkers, magnetic nanoparticles, magnetic sensors, magnetoresistive random access memory, and magnetic integrated inductors. He has over 300 publications, and holds 65 issued or pending patents in these and interdisciplinary areas. He was named an inaugural Fred Terman Fellow, and was elected a Fellow of the Institute of Electrical and Electronics Engineers (IEEE) and a Fellow of American Physical Society (APS) for his seminal contributions to magnetic materials and nanosensors. His team won the Grand Challenge Exploration Award from Gates Foundation (2010), the XCHALLENGE Distinguished Award (2014), and the Bold Epic Innovator Award from the XPRIZE Foundation (2017).

Dr. Wang cofounded three high-tech startups in Silicon Valley, including MagArray, Inc. and Flux Biosciences, Inc. In 2018 MagArray launched a first of its kind lung cancer early diagnostic assay based on protein cancer biomarkers and support vector machine (SVM). In 2019, Flux Biosciences launched a human trial to offer at-home testing of fertility based on hormones and magneto-nanosensors. Through his participation in the Center for Cancer Nanotechnology Excellence (as co-PI of the CCNE) and the Joint University Microelectronics Program (JUMP), he is actively engaged in the transformative research of healthcare and is developing emerging memories for energy efficient computing.

 

 

Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology

Apr
22
Thu
2021
MIPS Seminar - Jennifer Dionne, PhD @ Zoom - See Description for Zoom Link
MIPS Seminar – Jennifer Dionne, PhD
Apr 22 @ 12:00 pm – 12:45 pm Zoom - See Description for Zoom Link
MIPS Seminar - Jennifer Dionne, PhD @ Zoom - See Description for Zoom Link

MIPS Seminar Series: Emerging nanophotonic platforms for infectious disease diagnostics: Re-imagining the conventional microbiology toolkit

Jennifer Dionne, PhD
Senior Associate Vice Provost for Research Platforms/Shared Facilities
Associate Professor of Material Science and Engineering and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Stanford University

 

Location: Zoom
Webinar URL: https://stanford.zoom.us/j/95883654314
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 958 8365 4314
Passcode: 105586

12:00pm – 12:45pm Seminar & Discussion
RSVP Here

 

ABSTRACT
We present our research controlling light at the nanoscale for infectious disease diagnostics, including detecting bacteria at low concentration, sensing COVID gene sequences, and visualizing in-vivo inter-cellular forces. First, we combine Raman spectroscopy and deep learning to accurately classify bacteria by both species and antibiotic resistance in a single step. We design a convolutional neural network (CNN) for spectral data and train it to identify 30 of the most common bacterial strains from single-cell Raman spectra, achieving antibiotic treatment identification accuracies exceeding 99% and species identification accuracies similar to leading mass spectrometry identification techniques. Our combined Raman-CNN system represents a proof-of-concept for rapid, culture-free identification of bacterial isolates and antibiotic resistance.  Second, we describe resonant nanophotonic surfaces, known as “metasurfaces” that enable multiplexed detection of SARS-CoV-2 gene sequences. Our metasurfaces utilize guided mode resonances excited in high refractive index nanostructures. The high quality factor modes produce a large amplification of the electromagnetic field near the nanostructures that increase the response to targeted binding of nucleic acids; simultaneously, the optical signal is beam-steered for multiplexed detection. We describe how this platform can be manufactured at scale for portable, low-cost assays. Finally, we introduce a new class of in vivo optical probes to monitor biological forces with high spatial resolution. Our design is based on upconverting nanoparticles that, when excited in the near-infrared, emit light of a different color and intensity in response to nano-to-microNewton forces. The nanoparticles are sub-30nm in size, do not bleach or photoblink, and can enable deep tissue imaging with minimal tissue autofluorescence. We present the design, synthesis, and characterization of these nanoparticles both in vitro and in vivo, focusing on the forces generated by the roundworm C. elegans as it feeds and digests its bacterial food.

 

ABOUT
Jennifer Dionne is the Senior Associate Vice Provost of Research Platforms/Shared Facilities and an associate professor of Materials Science and Engineering and, by courtesy, of Radiology at Stanford. She is also an Associate Editor of Nano Letters, director of the DOE-funded Photonics at Thermodynamic Limits Energy Frontier Research Center, and an affiliate faculty of the Wu Tsai Neurosciences Institute, the Institute for Immunity, Transplantation, and Infection, and Bio-X. Jen received her B.S. degrees in Physics and Systems Science and Mathematics from Washington University in St. Louis, her Ph. D. in Applied Physics at the California Institute of Technology in 2009, and her postdoctoral training in Chemistry at Berkeley.  Her research develops nanophotonic methods to observe and control chemical and biological processes as they unfold with nanometer scale resolution, emphasizing critical challenges in global health and sustainability. Her work has been recognized with the Alan T. Waterman Award, a NIH Director’s New Innovator Award, a Moore Inventor Fellowship, the Materials Research Society Young Investigator Award, and the Presidential Early Career Award for Scientists and Engineers, and was featured on Oprah’s list of “50 Things that will make you say ‘Wow’!”.  Beyond the lab, Jen enjoys exploring the intersection of art and science, long-distance cycling, and reliving her childhood with her two young sons.

 

Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology

May
11
Tue
2021
Cancer Early Detection Seminar Series - Michael Berger, Ph.D. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Michael Berger, Ph.D.
May 11 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Michael Berger, Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: “Building a Scalable Clinical Genomics Program: How tumor, normal, and plasma DNA sequencing are informing cancer care, cancer risk, and cancer detection”

 

Michael Berger, Ph.D.

Elizabeth and Felix Rohatyn Chair & Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Memorial Sloan Kettering Cancer Center

 

Zoom Details
Meeting URL: https://stanford.zoom.us/s/92559505314
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Meeting ID: 925 5950 5314
Passcode: 418727

11:00am – 12:00pm Seminar & Discussion
RSVP Here

 

ABSTRACT
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of oncogenomic mutations that can be targeted therapeutically. To accelerate enrollment to clinical trials of molecularly targeted agents and guide treatment selection, we have established a center-wide, prospective clinical sequencing program at Memorial Sloan Kettering Cancer Center using a custom, paired tumor-blood normal sequencing assay (MSK-IMPACT), which we have used to profile more than 50,000 patients with solid tumors. Yet beyond just the characterization of tumor-specific alterations, the inclusion of blood DNA has readily enabled the identification of germline risk alleles and somatic mutations associated with clonal hematopoiesis. To complement this approach, we have also implemented a ‘liquid biopsy’ cfDNA panel (MSK-ACCESS) for cancer detection, surveillance, and treatment selection and monitoring. In my talk, I will describe the prevalence of somatic and germline genomic alterations in a real-world population, the clinical benefits of cfDNA assessment, and how clonal hematopoiesis can inform cancer risk and confound liquid biopsy approaches to cancer detection.

 

ABOUT
Michael Berger, PhD, holds the Elizabeth and Felix Rohatyn Chair and is Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center, a multidisciplinary initiative to promote precision oncology through genomic analysis to guide the diagnosis and treatment of cancer patients. He is also an Associate Attending Geneticist in the Department of Pathology with expertise in cancer genomics, computational biology, and high-throughput DNA sequencing technology. His laboratory is developing experimental and computational methods to characterize the genetic makeup of individual cancers and identify genomic biomarkers of drug response and resistance. As Scientific Director of Clinical NGS in the Molecular Diagnostics Service, he oversees the development and bioinformatics associated with clinical sequencing assays, and he helped lead the development and implementation of MSK-IMPACT, a comprehensive FDA-authorized tumor sequencing panel that been used to profile more than 60,000 tumors from advanced cancer patients at MSK. The resulting data have enabled the characterization of somatic and germline biomarkers across many cancer types and the identification of mutations associated with clonal hematopoiesis. Dr. Berger also led the development of a clinically validated plasma cell-free DNA assay, MSK-ACCESS, which his laboratory is using to explore tumor evolution, acquired drug resistance, and occult metastatic disease. He received his Bachelor’s Degree in Physics from Princeton University and his Ph.D. in Biophysics from Harvard University.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

May
12
Wed
2021
MIPS Special Seminar - Jubilant Biosys @ Zoom - See Description for Zoom Link
MIPS Special Seminar – Jubilant Biosys
May 12 @ 9:00 am – 10:00 am Zoom - See Description for Zoom Link
MIPS Special Seminar - Jubilant Biosys @ Zoom - See Description for Zoom Link

MIPS Special Seminar: Jubilant Biosys: Drug discovery and contract research services, from target discovery to candidate selection

 

Thomas Haywood, PhD
Head of International Radiochemistry Collaborations
Stanford University

 

Saurabh Kapure, MBA
Vice President, Business Development (USA & APAC)
Jubilant Biosys Limited

 

Jay Sheth, MBA
Manager Business Development, Drug Discovery Services, and CDMO
Jubilant Biosys Limited

 

LOCATION: Zoom
Meeting URL: https://stanford.zoom.us/j/98108346345
Dial: +1 650 724 9799 or +1 833 302 1536
Meeting ID: 981 0834 6345
Passcode: 397741

SCHEDULE
9:00-9:15  AM, PT Thomas Haywood – Stanford Radiology projects
9:15-9:30 AM, PT – Saurabh Kapure – Introduction to Jubilant Biosys, Scale-up and GMP manufacturing
9:30-9:40 AM, PT Jay Sheth – How Jubilant Biosys works with academic partners: examples and case-studies
9:40-10:00 AM, PT – Moderated by Jason Thanh Lee  – Discussion

 

ABOUT
Jubilant Biosys, an integrated contract research organization in India with business offices in Asia and North America, is a leading collaborator for biotechnology and pharmaceutical companies, with in-depth expertise in discovery informatics, medicinal chemistry, structural biology, and in vitro pharmacology services. Jubilant Biosys provides comprehensive drug discovery services and contract research services, from target discovery to candidate selection and with flexible business models (FFS, FTE and risk shared). This seminar will showcase case studies from recent Stanford projects and a discussion of future opportunities.

 

Sponsored by: Molecular Imaging Program at Stanford, Department of Radiology

May
27
Thu
2021
MIPS Seminar - Geoffrey Sonn, MD @ Zoom - See Description for Zoom Link
MIPS Seminar – Geoffrey Sonn, MD
May 27 @ 12:00 pm – 12:45 pm Zoom - See Description for Zoom Link
MIPS Seminar - Geoffrey Sonn, MD @ Zoom - See Description for Zoom Link

MIPS Seminar Series: Image-guided focal therapy for prostate cancer

Geoffrey Sonn, MD
Assistant Professor of Urology and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Stanford University Medical Center

 

Location: Zoom
Webinar URL: https://stanford.zoom.us/s/96126703618
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 961 2670 3618
Passcode: 186059

12:00pm – 12:45pm Seminar & Discussion
RSVP Here

 

ABSTRACT

In recent years, prostate cancer treatment has increasingly focused on selecting patients who are most likely to benefit and reducing harms from treatment. This has been seen both in adoption of active surveillance for men with low-risk prostate cancer and emergence of image-guided focal ablative therapy. While focal therapy causes fewer sexual and urinary side effects than conventional prostate cancer treatments, many questions remain about proper patient selection, treatment planning, and follow up care.

 

Improvements in prostate MRI performance and interpretation have paved the way for adoption of focal therapy. However, clinical challenges remain in prostate cancer imaging. This talk will describe prostate cancer focal therapy, discuss patient selection, and highlight the research efforts of my group to improve MRI interpretation to guide biopsy and improve focal therapy performance.

 

ABOUT
Geoffrey Sonn, MD is a urologic oncologist who specializes in treating patients with prostate and kidney cancer. He has a particular interest in cancer imaging, MRI-Ultrasound fusion targeted prostate biopsy, prostate cancer focal therapy, and robotic surgery for prostate and kidney cancer. He is the principal investigator of the first clinical trial in Northern California to use MRI-guided focused ultrasound to treat prostate cancer. The goal of this trial is to treat prostate cancer with fewer side effects than surgery or radiation.

Dr. Sonn was born in Washington State and lived there until leaving for college at Georgetown. After graduating magna cum laude at Georgetown he returned to the West Coast for medical school at UCLA. Following medical school, Dr. Sonn completed a 6-year urology residency at Stanford where he developed particular interests in the clinical care of patients with urologic cancers and research in cancer imaging. Dr. Sonn completed a 2-year urologic oncology fellowship at UCLA. Since completing his fellowship, Dr. Sonn has been at Stanford as an assistant professor in urology. Dr. Sonn’s research is devoted to developing new cancer imaging techniques, applying artificial intelligence to find cancers on medical images, and applying new methods to treat prostate cancer with fewer side effects.

 

Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology

Jun
3
Thu
2021
IMMERS - Stanford Medical Mixed Reality Panel Discussion Series @ Zoom
IMMERS – Stanford Medical Mixed Reality Panel Discussion Series
Jun 3 @ 9:00 am – 10:30 am Zoom
IMMERS - Stanford Medical Mixed Reality Panel Discussion Series @ Zoom

Join us for a panel on Behavioral XR on Thursday, June 3rd from 9:00 – 10:30 am PDT.  The event will start with a one-hour panel discussion featuring Dr. Elizabeth McMahon, a psychologist with a private practice in California; Sarah Hill of Healium, a company developing XR apps for mental fitness based in Missouri; Christian Angern of Sympatient, a company developing VR for anxiety therapy based in Germany; and Marguerite Manteau-Rao of Penumbra, a medical device company based in California.  This panel will be moderated by Dr. Walter Greenleaf of Stanford’s Virtual Human Interaction Lab (VHIL) and Dr. Christoph Leuze of the Stanford Medical Mixed Reality (SMMR) program.  Immediately following the panel discussion, you are also invited to a 30-minute interactive session with the panelists where questions and ideas can be explored in real time.

 

Register here to save your place now!  After registering, you will receive a confirmation email containing information about joining the meeting.

 

Please visit this page to subscribe to our events mailing list.

 

Sponsored by Stanford Medical Mixed Reality (SMMR)

Sep
23
Thu
2021
MIPS Seminar - David K. Stevenson, MD @ Zoom - See Description for Zoom Link
MIPS Seminar – David K. Stevenson, MD
Sep 23 @ 12:00 pm – 12:45 pm Zoom - See Description for Zoom Link
MIPS Seminar - David K. Stevenson, MD @ Zoom - See Description for Zoom Link

MIPS Seminar Series: Predicting and Preventing Fetal and Neonatal Pathology: Looking Back and Looking Forward

David K. Stevenson, MD
The Harold K. Faber Professor of Pediatrics, Senior Associate Dean, Maternal and Child Health and Professor, by courtesy, of Obstetrics and Gynecology
Lucile Packard Children’s Hospital

 

Zoom Webinar Details
Webinar URL: https://stanford.zoom.us/s/94584828060
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 945 8482 8060
Passcode: 481874

12:00pm – 12:45pm Seminar & Discussion
RSVP Here

 

ABSTRACT
The importance of minimally invasive technologies for interrogating the fetus and newborn, as well as of knowing where a biologic system is headed, not just where it has been, when trying to predict and prevent acquired diseases, will be discussed.  Examples of such technologies, such as trace gas analysis and optical reporting of biologic phenomena, and their application to model systems and the human newborn will be presented.  The role of advanced computational approaches for the integration and interpretation of large amounts of data derived from these new measurement tools will be emphasized.

 

ABOUT
Dr. David K. Stevenson is the Harold K. Faber Professor of Pediatrics and has made many impactful contributions to the field of neonatology and pediatrics, including his seminal studies on neonatal jaundice, bilirubin production and heme oxygenase biology.  As a neonatologist, his research has focused primarily on neonatal jaundice and more recently on the causes of preterm birth and its prevention.  He has held numerous leadership roles at Stanford University School of Medicine, including Vice Dean and Senior Associate Dean for Academic Affairs. He is currently the Senior Associate Dean for Maternal & Child Health, the Co-Director of the Stanford Maternal & Child Health Research Institute, and the Principal Investigator for the March of Dimes Prematurity Research Center at Stanford University.  Dr. Stevenson has received many awards, including the Virginia Apgar Award, which is the highest award in Perinatal Pediatrics, the Joseph W. St. Geme, Jr. Leadership Award from the Federation of Pediatric Organizations, the Jonas Salk Award for Leadership in Prematurity Prevention from the March of Dimes Foundation, and the John Howland Medal and Award, the highest award in academic pediatrics.  He has served as the President of the American Pediatric Society. In recognition of his achievements, Dr. Stevenson is a member of the National Academy of Medicine.

 

Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology

Oct
12
Tue
2021
Cancer Early Detection Seminar Series - Azra Raza, MD @ Venue coming soon!
Cancer Early Detection Seminar Series – Azra Raza, MD
Oct 12 @ 11:00 am – 12:00 pm Venue coming soon!
Cancer Early Detection Seminar Series - Azra Raza, MD @ Venue coming soon!

CEDSS: The First Cell: A new model for cancer research and treatment

Azra Raza, M.D.
Chan Soon-Shiong Professor of Medicine
Director, Myelodysplastic Syndrome Center
Columbia University Medical Center

 

Location: Zoom
Meeting URL: https://stanford.zoom.us/s/99340345860
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Meeting ID: 993 4034 5860
Passcode: 711508

RSVP Here

 

ABSTRACT

Cancer research continues to be predicated on a 1970’s model of research and treatment. Despite half a century of intense research, we are failing spectacularly to improve the outcome for patients with advanced disease. Those who are cured continue to be treated mostly with the older strategies (surgery-chemo-radiation). Our contention is that the real solution to the cancer problem is to diagnose cancer early, at the stage of The First Cell. The rapidly evolving technologies are doing much in this area but need to be expanded. We study a pre-leukemic condition called myelodysplastic syndrome (MDS) with the hope that we can detect the first leukemia cells as the disease transforms to acute myeloid leukemia (AML). Towards this end, we have collected blood and bone marrow samples on MDS and AML patients since 1984. Today, our Tissue Repository has more than 60,000 samples. We propose novel methods to identify surrogate markers that can identify the First Cell through studying the serial samples of patients who evolve from MDS to AML.

 

ABOUT

Dr. Raza is a Professor of Medicine and Director of the MDS Center at Columbia University in New York, NY.She started her research in Myelodisplastic Syndromes (MDS) in 1982 and moved to Rush University, Chicago, Illinois in 1992, where she was the Charles Arthur Weaver Professor in Oncology and Director, Division of Myeloid Diseases. The MDS Program, along with a Tissue Repository containing more than 50,000 samples from MDS and acute leukemia patients was successfully relocated to the University of Massachusetts in 2004 and to Columbia University in 2010.

Before moving to New York, Dr. Raza was the Chief of Hematology Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachussetts in Worcester. She has published the results of her laboratory research and clinical trials in prestigious, peer reviewed journals such as The New England Journal of Medicine, Nature, Blood, Cancer, Cancer Research, British Journal of Hematology, Leukemia, and Leukemia Research. Dr. Raza serves on numerous national and international panels as a reviewer, consultant and advisor and is the recipient of a number of awards.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Oct
28
Thu
2021
MIPS Seminar - Steven Paul Poplack, MD @ Venue coming soon!
MIPS Seminar – Steven Paul Poplack, MD
Oct 28 @ 12:00 pm – 12:45 pm Venue coming soon!
MIPS Seminar - Steven Paul Poplack, MD @ Venue coming soon!

MIPS Seminar Series: Title TBA

Steven Paul Poplack, MD
Professor of Radiology (Breast Imaging)
Stanford University Medical Center

 

Location: Coming soon!

12:00pm – 12:45pm Seminar & Discussion
RSVP: Coming soon!

 

ABSTRACT

Coming soon!

 

ABOUT
Coming soon!

 

Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology

Nov
18
Thu
2021
MIPS Seminar - Matthew Bogyo, PhD @ Venue coming soon!
MIPS Seminar – Matthew Bogyo, PhD
Nov 18 @ 12:00 pm – 12:45 pm Venue coming soon!
MIPS Seminar - Matthew Bogyo, PhD @ Venue coming soon!

MIPS Seminar Series: Title TBA

Matthew Bogyo, PhD
Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems Biology
Stanford University

 

Location: Coming soon!

12:00pm – 12:45pm Seminar & Discussion
RSVP: Coming soon!

 

ABSTRACT

Coming soon!

 

ABOUT
Dr. Bogyo received a B.Sc. degree in Chemistry from Bates College in 1993 and a Ph.D. in Biochemistry from the Massachusetts Institute of Technology in 1997. After completion of his degree he was appointed as a Faculty Fellow in the Department of Biochemistry and Biophysics at the University of California, San Francisco. Dr. Bogyo served as the Head of Chemical Proteomics at Celera Genomics from 2001 to 2003 while maintaining an Adjunct Faculty appointment at UCSF. In the Summer of 2003 Dr. Bogyo joined the Department of Pathology at Stanford Medical School and was appointed as a faculty member in the Department of Microbiology and Immunology in 2004. His interests are focused on the use of chemistry to study the role of proteases in human disease. In particular his laboratory is currently working on understanding the role of cysteine proteases in tumorgenesis and also in the life cycle of human parasites and bacterial pathogens. Dr. Bogyo currently serves on the Editorial Board of Biochemical Journal, Cell Chemical Biology, Molecular and Cellular Proteomics and is an Academic Editor at PLoS One. Dr. Bogyo is a consultant for several biotechnology and pharmaceutical companies in the Bay Area and is a founder and board member of Akrotome Imaging and Facile Therapeutics.

 

Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology